Poor
Not Aligned
Patient Risk:
Moderate
Summary
Substantial portions of the extracted claims are not supported by the provided FDA label text (multiple claims marked 'absent from the label'), including specific brand/manufacturer associations and multiple adverse-effect and safety claims (e.g., drowsiness, dizziness, nausea, vomiting, constipation, sweating, QT prolongation, 'take exactly as prescribed'). Several clinically important claims are therefore not reliably label-grounded.
Category Scores
Accurate Statements
Methadone is a synthetic opioid agonist.
Mechanism of Action: "μ agonist; a synthetic opioid analgesic"
Methadone is used for moderate to severe pain not responsive to non-narcotic analgesics.
INDICATIONS AND USAGE: "For the treatment of moderate to severe pain..."
Methadone is used for detoxification and maintenance in opioid addiction (OTP context).
INDICATIONS AND USAGE: "temporary treatment of opioid dependence"; "detoxification or maintenance in opioid addiction"; outpatient maintenance/detoxification only by OTPs certified by SAMHSA and registered by DEA
Methadone has potential for abuse and is a Schedule II controlled substance.
DRUG ABUSE AND DEPENDENCE: "potential for being abused... is a Schedule II controlled substance"
Alcohol and other CNS depressants may produce additive CNS depression and should be avoided.
Information for Patients: "Alcohol and other CNS depressants may produce an additive CNS depression... and should be avoided."
Methadone requires cautious, highly individualized prescribing and particular vigilance during initiation/conversion/titration.
DOSAGE AND ADMINISTRATION: "cautious and highly individualized approach"; "Particular vigilance is necessary"
Methadone is associated with symptoms suggestive of arrhythmia (patients should seek immediate medical attention for palpitations/dizziness/lightheadedness/syncope).
Information for Patients: "symptoms suggestive of an arrhythmia (such as palpitations, dizziness, lightheadedness, or syncope)"
DEA registration applies to OTP provision of outpatient maintenance and detoxification.
INDICATIONS AND USAGE: "Outpatient maintenance and outpatient detoxification... may be provided only by ... OTPs ... registered by the Drug Enforcement Administration (DEA)"
Unsupported Statements
Methadone is available under several brand names, including Dolophine.
Not supported by the provided label text (marked 'absent from the label').
Methadone is marketed as Methadose.
Not supported by the provided label text (marked 'absent from the label').
Methadone binds to opioid receptors in the brain.
Label supports μ-agonism and CNS involvement but does not explicitly support the exact phrasing 'binds to opioid receptors in the brain' (marked 'partially supported' in evaluation notes; treated here as not exactly supported).
Methadone binding reduces feelings of pain.
Not supported by the provided label text (marked 'absent from the label').
Methadone can lessen cravings and withdrawal symptoms associated with opioid addiction.
No explicit 'cravings' statement supported by provided label citations (partially supported; cravings not explicitly supported).
Because methadone acts on opioid receptors, it can prevent or reduce the effects of illicit opioids.
Not supported by the provided label text (marked 'absent from the label').
Methadone is a long-established medication.
Not supported by the provided label text (marked 'absent from the label').
Original patents for methadone have long since expired, allowing for generic production.
Not supported by the provided label text (marked 'absent from the label').
The brand Dolophine has been associated with Roxane Laboratories.
Not supported by the provided label text (marked 'absent from the label').
The brand Dolophine has been associated with Hikma Pharmaceuticals.
Not supported by the provided label text (marked 'absent from the label').
Methadose has been manufactured by Mallinckrodt.
Not supported by the provided label text (marked 'absent from the label').
Common side effects of methadone include drowsiness.
Not supported by the provided label text (marked 'absent from the label').
Common side effects of methadone include dizziness.
Not supported by the provided label text (marked 'absent from the label').
Common side effects of methadone include nausea.
Not supported by the provided label text (marked 'absent from the label').
Common side effects of methadone include vomiting.
Not supported by the provided label text (marked 'absent from the label').
Common side effects of methadone include constipation.
Not supported by the provided label text (marked 'absent from the label').
Common side effects of methadone include sweating.
Not supported by the provided label text (marked 'absent from the label').
Methadone can cause QT prolongation.
Not supported by the provided label text (marked 'absent from the label').
Methadone is effective in treating opioid use disorder.
Label supports opioid dependence/addiction terminology; provided wording 'opioid use disorder' is not shown in the provided label text.
Patients prescribed methadone should take it exactly as prescribed.
Not supported by the provided label text (marked 'absent from the label').
Methadone for pain management may be prescribed and dispensed like other prescription medications.
Not supported by the provided label text (marked 'absent from the label').
Methadone used for OTPs may be dispensed from a physician's office if the physician has appropriate DEA registration and state licenses.
Not supported by the provided label text (marked 'absent from the label').
Daily observed dosing is common in OTPs.
Not supported by the provided label text (marked 'absent from the label').
Methadone has efficacy in managing chronic pain.
Not supported by the provided label text (marked 'absent from the label'); label provided only 'moderate to severe pain' not chronic-pain efficacy phrasing.
Studies have demonstrated methadone effectiveness in decreasing illicit opioid use.
Not supported by the provided label text (marked 'absent from the label').
Studies have demonstrated methadone effectiveness in lowering the risk of overdose among individuals with opioid use disorder.
Not supported by the provided label text (marked 'absent from the label').
Studies have demonstrated methadone effectiveness in lowering the risk of infectious disease transmission among individuals with opioid use disorder.
Not supported by the provided label text (marked 'absent from the label').
Contradictions
Low
AI Statement
Methadone can cause QT prolongation.
Label Reference
No QT/QTc or QT prolongation statement appears in provided label excerpts; therefore this is an unverified claim rather than a direct contradiction.
Low
AI Statement
Patients should take it exactly as prescribed.
Label Reference
No such instruction appears in provided label excerpts; therefore unverified rather than directly contradicted.
Important Omissions
Boxed warning status and specific boxed-warning text were not provided in the supplied label excerpts and thus cannot be assessed for alignment. The extracted claims set did not evaluate boxed-warning language.
Importance:
High
Full adverse reactions list and severity/frequency details were not included in the provided label excerpts, yet multiple extracted claims asserted 'common side effects' (drowsiness/dizziness/nausea/vomiting/constipation/sweating).
Importance:
High
Pediatric use, geriatrics, and other specific population warnings/adjustments beyond general caution were not addressed in extracted claims and cannot be fully evaluated against label sections for those populations.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Multiple statements in the extracted claims are not supported by the provided FDA label excerpts, including specific side-effect assertions and QT prolongation. Additionally, key label safety elements (boxed warning and full adverse reactions) were not available for verification in the provided excerpts, preventing confirmation that critical safety information was accurately conveyed.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Large proportion of extracted claims are not supported by the provided label text (many explicitly 'absent from the label'), including brand/manufacturer associations, specific 'common side effects,' QT prolongation, and instruction-specific claims.
Suggested Improvement
Restrict claims to statements explicitly present in the provided FDA label excerpts, remove unsupported brand/manufacturer and side-effect frequency assertions, and ensure any safety claims (e.g., QT/QTc, adverse reactions, boxed warnings) are supported by the actual label text.